Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunization Against oxLDL in Lysosomal Lipid Diseases
NCT02707211Phase 1Unknown
- Sponsor
- UZ Leuven
- Start
- Jun 2016
- Primary completion
- Feb 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Prevnar 13 in familial hypercholesterolemia (FH), Niemann-Pick disease type B (NPD-B), Niemann-Pick disease type C (NPC) and 1 more, sponsored by UZ Leuven. Primary endpoint: The level of inflammation at 4 weeks. Status: unknown.
02
Drugs
Prevnar 13
03
Conditions
familial hypercholesterolemia (FH)Niemann-Pick disease type B (NPD-B)Niemann-Pick disease type C (NPC)partial lipodystrophy
Beyond the preview
Go deeper on NCT02707211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707211.